Cumberland Pharmaceuticals (CPIX) Common Equity (2010 - 2026)

Cumberland Pharmaceuticals (CPIX) has 17 years of Common Equity data on file, last reported at $51.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 82.53% year-over-year to $51.7 million; the trailing twelve-month figure through Mar 2026 stood at $51.7 million (up 82.53% YoY), and the FY2025 full-year result was $24.9 million, up 10.35% from the prior year.
• Common Equity improved to $51.7 million in Q1 2026, from $24.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $51.7 million in Q1 2026 to a low of $22.5 million in Q4 2024.
• A 5-year average of $32.5 million and a median of $29.3 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity slumped 31.37% in 2024 and jumped 82.53% in 2026, its largest moves.
• Tracing CPIX's Common Equity over 5 years: stood at $36.0 million in 2022, then declined by 18.66% to $29.3 million in 2023, then declined by 22.95% to $22.5 million in 2024, then rose by 10.35% to $24.9 million in 2025, then soared by 107.92% to $51.7 million in 2026.
• Business Quant data shows CPIX's Common Equity at $51.7 million in Q1 2026, $24.9 million in Q4 2025, and $26.1 million in Q3 2025.